(Q43158113)

15 November 2017

title

Clinical and virological effects of long-term (over 5 years) lamivudine therapy (English)

1 reference

15 November 2017

0 references

1 reference

15

Hiromitsu Kumada

1 reference

15 November 2017

2

Fumitaka Suzuki

1 reference

15 November 2017

14

Kenji Ikeda

1 reference

15 November 2017

9

Masahiro Kobayashi

1 reference

15 November 2017

11

Yoshiyuki Suzuki

1 reference

15 November 2017

8

Norio Akuta

1 reference

15 November 2017

13

Yasuji Arase

1 reference

15 November 2017

6

Hitomi Sezaki

1 reference

15 November 2017

4

Yusuke Kawamura

1 reference

15 November 2017

12

Mariko Kobayashi

1 reference

15 November 2017

10

Satoshi Saito

1 reference

15 November 2017

Yoshimasa Hashimoto

1

1 reference

15 November 2017

Miharu Hirakawa

series ordinal

3

1 reference

15 November 2017

Hiromi Yatsuji

series ordinal

5

1 reference

15 November 2017

Tetuya Hosaka

series ordinal

7

1 reference

15 November 2017

publication date

1 April 2010

1 reference

Journal of Medical Virology

15 November 2017

published in

1 reference

15 November 2017

volume

82

1 reference

15 November 2017

issue

4

1 reference

15 November 2017

page(s)

684-691

1 reference

Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

15 November 2017

cites work

1 reference

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment

21 January 2018

1 reference

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

21 January 2018

1 reference

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

21 January 2018

1 reference

Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis

21 January 2018

1 reference

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants

21 January 2018

1 reference

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

21 January 2018

1 reference

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Body-mass index and progression of hepatitis B: a population-based cohort study in men.

21 January 2018

1 reference

Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S.

21 January 2018

1 reference

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

21 January 2018

1 reference

Hepatitis B: reflections on the current approach to antiviral therapy.

21 January 2018

1 reference

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMV.21681

1 reference

15 November 2017

1 reference